{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Participants Who Achieved ≥4*10^6 cells"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Participants Who Achieved <4*10^6 cells"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Number of participants achieving a target of ≥ 4\\*10\\^6 CD34+ cells/kg during apheresis for up to 4 consecutive days. Apheresis was performed six hours following treatment with plerixafor 240 µg/kg (alone). Target was calculated as the sum of all daily values collected from central laboratory data over up to 4 apheresis days.","groups":[{"description":"Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.","id":"OG000","title":"Participants With Multiple Myeloma (MM)"}],"paramType":"NUMBER","populationDescription":"All participants who received plerixafor","reportingStatus":"POSTED","timeFrame":"Day 1 up to day 4","title":"Number of Participants Who Achieved ≥4*10^6 CD34+ Cells/kg","type":"PRIMARY","unitOfMeasure":"participants"}